NASDAQ : INVA

Innoviva, Inc.

$21.89 USD

$0.15 (0.69%)

Volume
1.02M
Average Volume
819.32K
Market Capitalization
$1.62B
P/E Ratio
3.12
Dividend Yield
0.00%
Price Target
$37.00
Year High
$25.15
Year Low
$16.52
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$21.13

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Pavel Raifeld
Industry Biotechnology
Sector Healthcare
Current Symbol INVA
CUSIP 45781M101
CIK 0001080014
Web https://www.inva.com
Phone 650 238 9600
Currency USD
Employees 159
Country US

Liquidity

Debt-to-Equity Ratio 0.25
Payout Ratio 0.00
Current Ratio 21.13
Quick Ratio 20.07
Cash Ratio 16.50

Sales & Book Value

Annual Sales $425.13M
Price / Sales 3.81
Cash Flow 2.44
Price / Cash Flow 8.93
Price / Book 1.21

Price Target and Rating

Average Stock Price Forecast $37.00
High Stock Price Forecast $42.00
Low Stock Price Forecast $32.00
Forecast Upside/Downside -40.84%
Consensus Rating Buy
Rating Score(0-5) 4
Research Coverage 10 Analysts

Profitability

EPS (Most Recent Fiscal Year) $3.3
Trailing P/E Ratio 3.12
PEG Ratio 0.00
P/E Growth 0.00
Net Income $271.16M
Net Margin 118.91%
Pretax Margin 141.47%
Return on Equity 47.59%
Return on Assets 27.46%

Financials Score

AltmanZ Score 4.09
Piotroski Score 4.00
Working Capital 736.06M
Total Assets 1.84B
Ebit 606.56M
Market Cap 1.6B
Total Liabilities 494.93M

Poll Results

About Innoviva, Inc. (NASDAQ:INVA) Stock

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily ... LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

2026-06-18 09:00:00

Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines u

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

2026-06-18 08:00:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact.

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

2026-06-16 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent S.

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

2026-06-08 17:38:29

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Innoviva to Participate in Upcoming Investor Conferences

2026-06-01 12:01:00

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critica

Innoviva to Participate in Upcoming Investor Conferences

2026-06-01 11:00:00

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference.

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

2026-05-29 18:35:31

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

Innoviva (INVA) Tops Q1 Earnings Estimates

2026-05-06 22:45:43

Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.

Frequently Asked Questions

What is the current Innoviva, Inc. (INVA) stock price?

Innoviva, Inc.(NASDAQ:INVA) stock price is $21.89 in the last trading session. During the trading session, INVA stock reached the peak price of $25.15 while $16.52 was the lowest point it dropped to. The percentage change in INVA stock occurred in the recent session was 0.69% while the dollar amount for the price change in INVA stock was $0.15.

INVA's industry and sector of operation?

The NASDAQ listed INVA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of INVA?

Marianne Zhen | Chief Accounting Officer & Secretary
Pavel Raifeld | Chief Executive Officer & Director
Stephen Basso | Chief Financial Officer
Patricia Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc.
David Altarac | Chief Medical Officer of IST

How many employees does INVA have?

Number of INVA employees currently stands at 159. INVA operates from 1350 Old Bayshore Highway, Burlingame, CA 94010, US.

Link for INVA official website?

Official Website of INVA is: https://www.inva.com

How do I contact INVA?

INVA could be contacted at phone #650 238 9600 and can also be accessed through its website. INVA operates from 1350 Old Bayshore Highway, Burlingame, CA 94010, US.

How many shares of INVA are traded daily?

The average number of INVA shares traded daily for last 3 months was 819.32K.

What is the market cap of INVA currently?

The market value of INVA currently stands at $1.62B with its latest stock price at $21.89